CEO Executive AssistantInfectious disease is the one therapeutic area where a pharma CEO’s decisions can become front-page news before the data are in. Pandemic preparedness investments play out over years with no guarantee of commercial return. Antimicrobial resistance programs require sustained funding for products that, if they work, regulators and clinicians will want used as little as possible. Vaccine programs demand public health partnerships with agencies whose institutional cultures, procurement models, and communication norms are fundamentally different from commercial pharma. And the underlying commercial model, episodic revenue driven by outbreak cycles and seasonal demand rather than chronic treatment, creates a financial profile that is genuinely difficult to manage alongside a standard portfolio.
For pharma and biotech CEOs managing infectious disease and vaccine programs, the time allocation challenge is unusually complex. The domains requiring personal CEO attention are more varied than in most other therapeutic areas, the external relationships more consequential, and the governance decisions higher-stakes. What follows is a framework for how to build a CEO engagement model that is rigorous enough to actually drive outcomes in this space.
The Commercial Model Problem: Why Standard Portfolio Management Fails
Before addressing specific time domains, it is worth being precise about why infectious disease resists the portfolio management approaches that work elsewhere. In oncology or cardiovascular disease, a CEO can build a reasonably stable mental model of commercial opportunity: a target patient population, an addressable market, a reimbursement environment, a competitive landscape. The forecast is uncertain, but the framework is stable.
In infectious disease, the framework itself is unstable. A bacterial pneumonia antibiotic has a clear chronic use case, but antimicrobial stewardship pressure means that payers and hospital formulary committees will actively discourage its use except when no alternative exists. A respiratory syncytial virus vaccine has clear seasonal demand but faces pricing pressure from public health purchasers who operate under very different economic logic than commercial payers. A novel broad-spectrum antiviral may have enormous value in an outbreak scenario that may not materialize for five years, or may never materialize, or may arrive six months after you make the decision to shelve the program.
Managing this commercial model requires a CEO who is personally conversant with public health economics, not just commercial pharma economics. The financial models your business development and commercial teams will present to you are less reliable guides to strategic decisions in infectious disease than they are in other areas. That is not a failure of your team. It is a feature of the domain. The CEO’s role is to make credible strategic commitments in the presence of uncertainty that financial models cannot resolve, and to build the external relationships that reduce that uncertainty over time.
Time Allocation Framework: The Five Domains
Domain 1: Public Health Partnership Management
The agencies your infectious disease portfolio depends on, including WHO, CDC, CEPI, BARDA, and equivalent bodies in Europe and Asia, are not customers, partners, or regulators in the conventional sense. They are something more complex: simultaneously a source of funding, a shaper of demand signals, a channel to markets you cannot access commercially, and a source of reputational legitimacy that affects your ability to recruit talent, attract academic collaborators, and engage other governments.
Managing these relationships is not a government affairs function. It is a CEO function. The heads of CEPI, BARDA, and the WHO’s Health Emergencies Programme are making multi-hundred-million-dollar portfolio decisions that directly affect which programs receive coalition funding, which organizations are invited into pandemic preparedness consortia, and which CEOs are called when governments need a manufacturing partner during an outbreak response. Those calls go to CEOs with whom agency leaders have built a genuine working relationship over years, not to organizations whose government affairs teams have maintained institutional contact.
This means you need to be personally known to the leadership of your three to five most strategically important public health partners. Not known of. Known. This requires a deliberate relationship-building investment: attending the right conferences (World Health Assembly, the CEPI annual forum, ASTMH), accepting speaking invitations that put you on the same stage as agency leadership, and making direct contact when you have something substantive to offer or discuss, not only when you need something.
The time investment is approximately 10 to 15 percent of your external engagement calendar. What you are buying is not access. It is the ability to be a credible counterpart in the conversations that determine which organizations lead the next pandemic response, which vaccines receive WHO prequalification priority, and which AMR programs are included in government procurement commitments.
Domain 2: Pipeline Governance for Uncertain Assets
Infectious disease pipeline governance requires a different decision framework than oncology or metabolic disease governance, because the strategic value of an asset is partially a function of external events you cannot control. A broad-spectrum antiviral with demonstrated activity against multiple RNA viruses may be strategically critical if an outbreak of a novel pathogen occurs during its Phase II development, or it may generate modest commercial returns against endemic respiratory viruses if no outbreak materializes.
This uncertainty requires CEOs to think about pipeline governance in two parallel frames. The first is the standard clinical and regulatory progression framework: does this asset have adequate efficacy and safety data to support advancement, and is the regulatory pathway viable? The second is a strategic options framework: what is the value of maintaining this asset in the pipeline as an option on future outbreak scenarios, even if the expected value under current commercial projections is marginal?
These two frames frequently produce different answers, and the tension between them is a CEO-level governance question, not a CMO or CSO question. Your clinical team is trained to evaluate assets on evidence standards. Your business development team is trained to evaluate assets on commercial projections. The question of how much strategic option value to ascribe to a pandemic preparedness asset, and how long to sustain investment in the absence of commercial clarity, requires a CEO who can hold both frameworks simultaneously.
Direct engagement with pipeline governance decisions on your most strategically uncertain infectious disease assets should be monthly, with particular attention to the go/no-go decisions where the clinical evidence and commercial evidence point in different directions. These are the moments when your personal judgment about the strategic option value of the asset is the deciding factor.
Domain 3: Antimicrobial Resistance Program Governance
AMR governance deserves its own domain in any serious CEO time allocation framework, because the market failure in antibiotic development is not primarily a scientific problem. It is a structural problem that requires CEO-level engagement with a set of actors, including governments, multilateral bodies, hospital systems, and payer coalitions, that no other organizational leader has the standing to engage effectively.
The economics of antibiotic development are well documented: the global drug pipeline is insufficient to address the scale of antimicrobial resistance, and the commercial returns from novel antibiotics have been inadequate to sustain the investment required. Several biotech companies developing novel antibiotics have gone bankrupt in recent years despite having successful clinical programs, because the commercial market did not generate sufficient returns to cover development costs. The PASTEUR Act in the United States and equivalent pull incentive models in the UK and elsewhere represent the most promising structural solutions, but they require active advocacy from industry CEOs to sustain political momentum.
If your organization has AMR programs, you should be doing two things at the CEO level. First, participating in the policy advocacy coalitions working on pull incentive legislation, including GARDP, the AMR Action Fund, and industry coalitions engaging with the G7 and G20 on AMR policy. This is not primarily a reputational investment. It is a strategic investment in the market structures that will determine whether your AMR programs can generate sustainable returns. Second, building the hospital system and payer relationships that will shape how your eventual products are positioned within stewardship frameworks. Antibiotic formulary decisions are made by infection control committees and pharmacy and therapeutics committees that are not easily reached by commercial channels. A CEO who has built credibility with hospital CMOs and Chief Pharmacy Officers has a meaningful advantage in this environment.
Domain 4: Regulatory Strategy for Novel Pathogen Programs
Regulatory strategy in infectious disease has unique features driven by the outbreak context in which many programs are developed and reviewed. The FDA’s Emergency Use Authorization pathway, the FDA Animal Rule for biodefense products, the EMA’s conditional marketing authorization, and WHO Emergency Use Listing all represent regulatory mechanisms designed for a different risk-benefit context than standard drug development. Using them effectively requires a CEO who is personally engaged with the regulatory strategy, not just briefed on it.
The stakes are high because regulatory missteps in an outbreak context are immediately public and can permanently damage an organization’s relationship with public health agencies and governments. A CEO who does not understand the limitations of EUA approval, the post-authorization commitment structure it requires, and the potential reputational exposure of seeking EUA for a product with limited efficacy data, is a liability to their organization and to public health.
Conversely, a CEO who has built a direct relationship with FDA Center for Biologics Evaluation and Research leadership, understands the agency’s current thinking on accelerated approval pathways for novel pathogens, and can make credible commitments about post-authorization study conduct is positioned to navigate these pathways effectively. Engagement with regulatory strategy oversight is essential here, particularly for your most novel and time-sensitive programs.
Practically, this means quarterly direct engagement with your Head of Regulatory Affairs on infectious disease programs, annual personal engagement with FDA and EMA leadership on your highest-priority pipeline assets, and direct participation in any Type A or Type B meeting preparation where the agenda touches on breakthrough therapy designation, accelerated approval, or emergency use pathways.
Domain 5: Pandemic Preparedness Investment Governance
Pandemic preparedness is the domain where CEO time allocation decisions have the longest time horizons and the least financial clarity. The question of how much to invest in platform technologies, manufacturing capacity, and broad-spectrum programs that may not have near-term commercial applications is genuinely one of the hardest strategic decisions in the life sciences industry.
The organizations that were positioned to respond to COVID-19 rapidly in 2020, including Moderna with its mRNA platform, AstraZeneca through its academic partnerships, and Johnson and Johnson through its AdVac platform, had made sustained investments over years in capabilities whose commercial value had been uncertain at the time of investment. The CEOs who made those investments were not making purely commercial decisions. They were making strategic bets on platform value and public health partnership credibility that created optionality in a scenario that was always possible but not commercially foreseeable.
The framework for making these decisions well requires CEOs to think about pandemic preparedness investment as a portfolio of options, not a set of commercial programs. The relevant questions are not “what is the expected NPV of this mRNA platform investment?” but rather “what capabilities does this investment create, how durable are those capabilities, and what is the range of scenarios in which they create strategic value?”
According to the WHO’s 2023 World Health Statistics, infectious diseases remain a leading cause of mortality globally and pandemic risk is assessed as increasing due to factors including climate change, urbanization, and antimicrobial resistance. The strategic case for sustained investment in infectious disease capabilities is not diminishing.
As CEO, you should be making the pandemic preparedness investment decisions personally, with your CFO and CSO as primary inputs, rather than delegating them to a business development or portfolio planning process. These decisions require a CEO’s perspective on long-term strategic positioning, organizational capability building, and public health partnership credibility that a standard portfolio governance process is not designed to surface.
The Revenue Volatility Problem: Managing the Board Conversation
One of the most practically difficult aspects of leading an infectious disease portfolio is managing board and investor expectations around revenue volatility. A respiratory virus season that is milder than expected can produce a significant commercial shortfall against plan. An outbreak-driven demand spike can produce a windfall that analysts will not credit as recurring revenue. The episodic and often unpredictable nature of infectious disease revenue makes standard financial performance metrics unreliable signals of portfolio health.
CEOs leading infectious disease organizations need to develop a board and investor communication framework that separates the discussion of strategic portfolio positioning from the discussion of quarterly commercial performance. This requires establishing pipeline progression metrics, public health partnership indicators, and platform capability milestones as the primary strategic KPIs, with commercial performance understood as a noisy signal that reflects both organizational execution and exogenous factors outside management control.
This is a CEO communication responsibility that cannot be delegated. Your CFO can present the numbers. Only the CEO can build the narrative framework that helps your board understand what those numbers mean in the context of a commercial model that is fundamentally different from the rest of your industry.
Building the Right External Network
The external network a pharma CEO needs to lead effectively in infectious disease is different from the network required in other therapeutic areas. In addition to the standard CEO network of peer company leaders, key opinion leaders, and major investors, you need direct relationships with a set of public health actors whose institutional cultures and relationship norms are distinct from commercial pharma.
These relationships take time to build and require genuine investment. Showing up at WHO meetings with a commercial agenda is immediately visible and counterproductive. The public health officials who are most valuable to your organization’s long-term strategic positioning are precisely the ones who have seen enough pharma executives with commercial agendas to be appropriately skeptical of them. Building credibility in this network requires demonstrating, through sustained action over years, that your organization is a reliable partner in the public health mission, not merely a commercial entity seeking preferential access.
The CEOs who have done this effectively, and who consequently lead the organizations that are first-called during outbreak responses, first-considered for coalition funding, and most credibly positioned to advocate for pull incentives, are those who built this credibility before they needed it. That is the fundamental time allocation insight for infectious disease leadership: the investments that matter most are the ones made years before their strategic value becomes apparent.
What This Requires From You Personally
Leading an infectious disease portfolio at the CEO level requires three capabilities that are harder to develop than domain knowledge. The first is comfort with fundamental commercial uncertainty, and the ability to make large resource allocation decisions without the financial clarity you would have in other therapeutic areas. The second is the relational credibility to be a genuine partner to public health institutions rather than a supplicant or a vendor. The third is the long time horizon to invest in platform capabilities and public health partnerships whose returns may not materialize during your tenure.
These are not capabilities that standard pharma CEO development produces reliably. The CEOs excelling in infectious disease are those who have deliberately built these capabilities through the kind of sustained personal engagement described in this framework. The organizations they lead are building competitive positions that will matter most precisely when the world most needs them to.